Get the Stockscreener App
4.88
8.69%
0.39
Cellectar Biosciences Inc stock is traded at $4.88, with a volume of 66,724.
It is up +8.69% in the last 24 hours and down -6.15% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$4.49
Open:
$4.48
24h Volume:
66,724
Relative Volume:
0.01
Market Cap:
$15.58M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.5015
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+12.44%
1M Performance:
-6.15%
6M Performance:
+1,467%
1Y Performance:
+133.49%
1-Day Range:
$4.48
$4.89
1-Week Range:
$4.11
$4.92
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.88 | 13.43M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
What high frequency data says about Cellectar Biosciences Inc.Index Update & Community Shared Stock Ideas - Newser
Visualizing Cellectar Biosciences Inc. stock with heatmapsTrade Signal Summary & Daily Profit Focused Stock Screening - Newser
What’s next for Cellectar Biosciences Inc. stock priceMarket Sentiment Report & Weekly Momentum Picks - Newser
Using Ichimoku Cloud for Cellectar Biosciences Inc. technicals2025 AllTime Highs & Advanced Swing Trade Entry Alerts - Newser
Does Cellectar Biosciences Inc. show high probability of rebound2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
Using AI based signals to follow Cellectar Biosciences Inc.2025 Key Lessons & Technical Pattern Based Signals - Newser
Will Cellectar Biosciences Inc. see short term momentumTrade Volume Summary & Weekly Top Gainers Alerts - Newser
XTX Topco Ltd Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Earnings Chart Overlay Points to Cellectar Biosciences Inc. UpsideQuarterly Portfolio Review & Weekly Consistent Profit Watchlists - 선데이타임즈
How high can Cellectar Biosciences Inc. stock go2025 Technical Patterns & Risk Managed Investment Signals - Newser
How sentiment analysis helps forecast Cellectar Biosciences Inc.Recession Risk & Low Drawdown Investment Ideas - Newser
Advanced analytics toolkit walkthrough for Cellectar Biosciences Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
Support Zone Holds Steady for Cellectar Biosciences Inc. After Dip2025 Winners & Losers & Daily Entry Point Trade Alerts - 선데이타임즈
Key metrics from Cellectar Biosciences Inc.’s quarterly dataWeekly Profit Recap & Verified High Yield Trade Plans - Newser
Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target - AInvest
Cellectar Cuts Q2 Losses and Expenses - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript - MSN
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus - MSN
Cellectar Biosciences Reports Q2 2025 Financial Results - TipRanks
Cellectar Biosciences Reports Q2 EPS $3.39, Below Consensus $3.70 - AInvest
Cellectar Biosciences Q2 2025 Earnings Report - MarketBeat
Cellectar Biosciences shares fall 1.81% after-hours following Q2 2025 earnings call. - AInvest
Cellectar's 2025 Q2 Earnings Call: Key Contradictions in Phase 3 Trial Strategy and Cost Projections - AInvest
Cellectar to Submit NDA for Iopofosine I-131 in WM by Early 2026, Focuses on Accelerated Approval - AInvest
Earnings call transcript: SelectR Biosciences Q2 2025 reports $5.4M loss - Investing.com
Cellectar Biosciences shares rise 7.47% premarket after reporting positive updates on Iopofosine I 131 and CLR 125. - AInvest
Cellectar Achieves Q2 Loss Reduction, R&D Expenses Drop 67.1% - AInvest
Cellectar Biosciences Reports Q2 GAAP EPS of -$3.39, Beats Estimate by $0.31, with Cash and Cash Equivalents of $11M as of June 30. - AInvest
Cellectar Biosciences Advances Iopofosine I 131 for WM, CLR 125 for TNBC. - AInvest
Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path - Stock Titan
Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionTrade Risk Report & Weekly Top Gainers Trade List - Newser
Cellectar Biosciences Q2 2025 Earnings Preview: Analysts Expect $-3.66 EPS - AInvest
How to manage a losing position in Cellectar Biosciences Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - Newser
Published on: 2025-08-13 08:37:11 - Newser
Cellectar Biosciences Inc. stock chart pattern explained2025 Market Overview & Long-Term Growth Portfolio Plans - Newser
How to recover losses in Cellectar Biosciences Inc. stockSummary of Trade Cycles in 5-Year Range - Newser
What moving averages say about Cellectar Biosciences Inc.Free Investment Strategy With Low Risk - Newser
Multi factor analysis applied to Cellectar Biosciences Inc.High Return Trade Roadmap with Setup Filters - Newser
Cellectar Biosciences Inc. stock trend forecastTechnical Trend Forecast for Investors - Newser
What recovery options are there for Cellectar Biosciences Inc.Daily Stock Movement Forecast with Accuracy - Newser
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
A | What is Cellectar Biosciences, Inc.'s revenue forecastBest ROI Stock Strategies - newsyoung.net
Will a bounce in Cellectar Biosciences Inc. offer an exitPattern Recognition Tool for ROI Investors - Newser
Cellectar Biosciences reports Q2 financial results, conference call on August 14. - AInvest
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - Yahoo Finance
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Is Cellectar Biosciences Inc. trending in predictive chart modelsFree Smart Money Tracking Signal Generator - Newser
Cellectar Biosciences Inc. Shows Early Signs of Technical StrengthInvestment Plan With Growth Optimization Finalized - metal.it
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):